NCT05460273 · OUTCOME

Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: GEOMETRIC_MEAN
Unit: ug/mL
Interval / dispersion: Geometric Coefficient of Variation
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

What was measured

PK parameters of Total Anti-TROP2 Antibody\_Maximum observed concentration

Analysis population: PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.

Groups in this outcome

TNBC Cohort

Final Analysis with DCO on 06May2024

NSCLC Cohort

Final Analysis with DCO on 27Nov2024

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
TNBC Cohort	8
NSCLC Cohort	9

Reported measurements

Source class 1

Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
TNBC Cohort	151.1	11.62	Not reported	Not reported	Not reported
NSCLC Cohort	115.5	22.99	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
11.62
value
151.1
group Id
OG001
spread
22.99
value
115.5

denoms

counts
group Id
OG000
value
8
group Id
OG001
value
9
units
Participants

description

PK parameters of Total Anti-TROP2 Antibody\_Maximum observed concentration

dispersion Type

Geometric Coefficient of Variation

groups

description
Final Analysis with DCO on 06May2024
id
OG000
title
TNBC Cohort
description
Final Analysis with DCO on 27Nov2024
id
OG001
title
NSCLC Cohort

param Type

GEOMETRIC_MEAN

population Description

PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.

reporting Status

POSTED

time Frame

TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

title

Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody

type

SECONDARY

unit Of Measure

ug/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice